{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:27:43Z","timestamp":1770409663357,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urology.2025.11.225","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:22:33Z","timestamp":1763346153000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploratory Randomized Comparison of Mirabegron and Vibegron as First-line Therapy for Overactive Bladder in Elderly Women"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-5845","authenticated-orcid":false,"given":"Hirotaka","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurie","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiyuki","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.11.225_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/nau.22609","article-title":"Do we need a new definition of the overactive bladder syndrome?","volume":"33","author":"Drake","year":"2014","journal-title":"Neurourol. Urodyn."},{"issue":"6","key":"10.1016\/j.urology.2025.11.225_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/JU.0000000000001344","article-title":"Significance of overactive bladder as a predictor of falls in community-dwelling older adults: 1-year follow-up of the Sukagawa study","volume":"205","author":"Omae","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/nau.24827","article-title":"The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications","volume":"41","author":"Welk","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.urology.2025.11.225_bib5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00192-021-05033-0","article-title":"Daily symptom associations for urinary urgency and anxiety, depression and stress in women with OAB","volume":"33","author":"Mehr","year":"2022","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.urology.2025.11.225_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/JU.0000000000000212","article-title":"Sleep disturbance worsens lower urinary tract symptoms: the Nagahama study","volume":"202","author":"Fukunaga","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-week safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib8","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Brubaker. Patient-reported reasons for discontinuing OAB medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.urology.2025.11.225_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of OAB with anticholinergic therapy: a systematic review","volume":"65","author":"Sexton","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.urology.2025.11.225_bib10","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.urology.2025.11.225_bib11","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomized, double-blind, placebo-controlled study of mirabegron in Japanese patients with OAB","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.urology.2025.11.225_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Kurose T. Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for OAB: a randomized, placebo-controlled phase III study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, placebo and active controlled study to evaluate vibegron in OAB: EMPOWUR trial","volume":"204","author":"Staskin","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/luts.12190","article-title":"Safety and effectiveness of mirabegron in patients aged \u226575 years: Japanese post-marketing study","volume":"11","author":"Yoshida","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.urology.2025.11.225_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for OAB: a systematic review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/luts.12480","article-title":"Mirabegron versus vibegron in previously untreated female patients with overactive bladder: a randomized, single-clinic, open-label trial","volume":"15","author":"Sato","year":"2023","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.urology.2025.11.225_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.urology.2023.02.003","article-title":"Comparison of mirabegron and vibegron in women with treatment-na\u00efve overactive bladder: a randomized controlled study","volume":"175","author":"Kinjo","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.11.225_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","article-title":"Symptom assessment tool for overactive bladder syndrome\u2014overactive bladder symptom score","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.11.225_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1023422208910","article-title":"Multinational study of reliability and validity of the King\u2019s Health Questionnaire in patients with overactive bladder","volume":"12","author":"Reese","year":"2003","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.urology.2025.11.225_bib21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.urology.2011.06.020","article-title":"Responsiveness and minimal clinically important change in overactive bladder symptom score","volume":"78","author":"Gotoh","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.11.225_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1471-0528.2004.00129.x","article-title":"How much is enough and who says so?","volume":"111","author":"Kelleher","year":"2004","journal-title":"BJOG."},{"key":"10.1016\/j.urology.2025.11.225_bib23","first-page":"2121","article-title":"Patient-reported outcomes in patients with overactive bladder treated with antimuscarinics: pooled analysis of 10 randomized, double-blind, placebo-controlled trials","volume":"38","author":"Carlson","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.urology.2025.11.225_bib24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.urology.2025.11.225_bib25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","article-title":"Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial","volume":"75","author":"Mitcheson","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, double-blind, placebo-controlled trial of vibegron in patients with overactive bladder","volume":"204","author":"Staskin","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.urology.2025.11.225_bib27","first-page":"1020","article-title":"Clinical efficacy and safety of the novel selective \u03b23-adrenoceptor agonist vibegron in Japanese patients with overactive bladder: a randomized, placebo-controlled, double-blind, phase IIb study","volume":"123","author":"Takeda","year":"2019","journal-title":"BJU Int."},{"key":"10.1016\/j.urology.2025.11.225_bib28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","article-title":"EAU guidelines on the assessment and nonsurgical management of urinary incontinence","volume":"73","author":"Nambiar","year":"2018","journal-title":"Eur. Urol."}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525012816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525012816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:05:20Z","timestamp":1770372320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525012816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"alternative-id":["S0090429525012816"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.11.225","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploratory Randomized Comparison of Mirabegron and Vibegron as First-line Therapy for Overactive Bladder in Elderly Women","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.11.225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}